BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 24746821)

  • 1. Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity.
    Turunen M; Spaeth JM; Keskitalo S; Park MJ; Kivioja T; Clark AD; Mäkinen N; Gao F; Palin K; Nurkkala H; Vähärautio A; Aavikko M; Kämpjärvi K; Vahteristo P; Kim CA; Aaltonen LA; Varjosalo M; Taipale J; Boyer TG
    Cell Rep; 2014 May; 7(3):654-60. PubMed ID: 24746821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19.
    Park MJ; Shen H; Spaeth JM; Tolvanen JH; Failor C; Knudtson JF; McLaughlin J; Halder SK; Yang Q; Bulun SE; Al-Hendy A; Schenken RS; Aaltonen LA; Boyer TG
    J Biol Chem; 2018 Mar; 293(13):4870-4882. PubMed ID: 29440396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mediator Kinase Disruption in MED12-Mutant Uterine Fibroids From Hispanic Women of South Texas.
    Park MJ; Shen H; Kim NH; Gao F; Failor C; Knudtson JF; McLaughlin J; Halder SK; Heikkinen TA; Vahteristo P; Al-Hendy A; Schenken RS; Boyer TG
    J Clin Endocrinol Metab; 2018 Nov; 103(11):4283-4292. PubMed ID: 30099503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.
    Kämpjärvi K; Kim NH; Keskitalo S; Clark AD; von Nandelstadh P; Turunen M; Heikkinen T; Park MJ; Mäkinen N; Kivinummi K; Lintula S; Hotakainen K; Nevanlinna H; Hokland P; Böhling T; Bützow R; Böhm J; Mecklin JP; Järvinen H; Kontro M; Visakorpi T; Taipale J; Varjosalo M; Boyer TG; Vahteristo P
    Prostate; 2016 Jan; 76(1):22-31. PubMed ID: 26383637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation analysis of components of the Mediator kinase module in MED12 mutation-negative uterine leiomyomas.
    Mäkinen N; Heinonen HR; Sjöberg J; Taipale J; Vahteristo P; Aaltonen LA
    Br J Cancer; 2014 Apr; 110(9):2246-9. PubMed ID: 24642626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas.
    Kämpjärvi K; Park MJ; Mehine M; Kim NH; Clark AD; Bützow R; Böhling T; Böhm J; Mecklin JP; Järvinen H; Tomlinson IP; van der Spuy ZM; Sjöberg J; Boyer TG; Vahteristo P
    Hum Mutat; 2014 Sep; 35(9):1136-41. PubMed ID: 24980722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A precisely positioned MED12 activation helix stimulates CDK8 kinase activity.
    Klatt F; Leitner A; Kim IV; Ho-Xuan H; Schneider EV; Langhammer F; Weinmann R; Müller MR; Huber R; Meister G; Kuhn CD
    Proc Natl Acad Sci U S A; 2020 Feb; 117(6):2894-2905. PubMed ID: 31988137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase 8 is an independent prognosticator in uterine leiomyosarcoma.
    Yasutake N; Iwasaki T; Yamamoto H; Sonoda K; Kodama K; Okugawa K; Asanoma K; Yahata H; Kato K; Oda Y
    Pathol Res Pract; 2022 Jul; 235():153920. PubMed ID: 35605413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MED12 somatic mutations encompassing exon 2 associated with benign breast fibroadenomas and not breast carcinoma in Indian women.
    Darooei M; Khan F; Rehan M; Zubeda S; Jeyashanker E; Annapurna S; Shah A; Maddali S; Hasan Q
    J Cell Biochem; 2019 Jan; 120(1):182-191. PubMed ID: 30230586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
    Yatsenko SA; Mittal P; Wood-Trageser MA; Jones MW; Surti U; Edwards RP; Sood AK; Rajkovic A
    Fertil Steril; 2017 Feb; 107(2):457-466.e9. PubMed ID: 27889101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.
    Croce S; Chibon F
    Eur J Cancer; 2015 Aug; 51(12):1603-10. PubMed ID: 26037152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours.
    Matsubara A; Sekine S; Yoshida M; Yoshida A; Taniguchi H; Kushima R; Tsuda H; Kanai Y
    Histopathology; 2013 Mar; 62(4):657-61. PubMed ID: 23347103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.
    Mäkinen N; Mehine M; Tolvanen J; Kaasinen E; Li Y; Lehtonen HJ; Gentile M; Yan J; Enge M; Taipale M; Aavikko M; Katainen R; Virolainen E; Böhling T; Koski TA; Launonen V; Sjöberg J; Taipale J; Vahteristo P; Aaltonen LA
    Science; 2011 Oct; 334(6053):252-5. PubMed ID: 21868628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of erythropoietin messenger ribonucleic acid in wild-type MED12 uterine leiomyomas under estrogenic influence: new insights into related growth disparities.
    Asano R; Asai-Sato M; Matsukuma S; Mizushima T; Taguri M; Yoshihara M; Inada M; Fukui A; Suzuki Y; Miyagi Y; Miyagi E
    Fertil Steril; 2019 Jan; 111(1):178-185. PubMed ID: 30554729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
    Mäkinen N; Vahteristo P; Kämpjärvi K; Arola J; Bützow R; Aaltonen LA
    Eur J Hum Genet; 2013 Nov; 21(11):1300-3. PubMed ID: 23443020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors.
    Je EM; Kim MR; Min KO; Yoo NJ; Lee SH
    Int J Cancer; 2012 Sep; 131(6):E1044-7. PubMed ID: 22532225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RISING STARS: Role of MED12 mutation in the pathogenesis of uterine fibroids.
    Ishikawa H; Kobayashi T; Kaneko M; Saito Y; Shozu M; Koga K
    J Mol Endocrinol; 2023 Nov; 71(4):. PubMed ID: 37668348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
    Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
    Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered chromatin landscape and enhancer engagement underlie transcriptional dysregulation in MED12 mutant uterine leiomyomas.
    Moyo MB; Parker JB; Chakravarti D
    Nat Commun; 2020 Feb; 11(1):1019. PubMed ID: 32094355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors.
    Schwetye KE; Pfeifer JD; Duncavage EJ
    Hum Pathol; 2014 Jan; 45(1):65-70. PubMed ID: 24196187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.